2023-06-07-艾昆纬-2023年全球肿瘤学趋势_75页_1mb

Global Oncology Trends 2023: Outlook to 2027

Introduction

• Serious concern about unequal access and care persists despite substantial innovation in novel cancer treatments.
• Oncology R&D and innovation continue to expand, developing increasingly advanced therapies for cancer treatment.

Oncology Research & Development

• Trials at record highs but face significant complexity due to increased number of eligibility criteria, endpoints, trial sites, and duration.
• Emerging biopharma companies (EBPs) increasingly lead innovation and R&D in oncology. China-headquartered companies also increase influence.
• Next-generation modalities like antibody-drug conjugates (ADCs), bispecific antibodies, and CAR-T therapies show strong focus.
• Global oncology trial starts in 2022 saw significant growth, predominantly targeting rare cancers and solid tumors.

Oncology Clinical Development

• Composite trial success rates remain low, about 3.5% in 2022, lowest among all therapy areas over a decade.
• Clinical development productivity is lowest among disease areas, driven by trial complexity and long durations.
• More complex trials with decreasing white space (administrative delays between phases), longer durations due to regulatory barriers.
• Significant adoption of novel trial designs, especially basket, umbrella, and master protocols.

Diversity & Inclusivity

• Significant socioeconomic and healthcare disparities exist across race and ethnicity, especially for Black/African American populations.
• Oncology trials show lower inclusion of Black/African American and Hispanic populations compared to overall cancer epidemiology.
• Key trial design decisions like criteria and sites correlate strongly with inclusive patient representation.
• Greater focus needed on structural changes to clinical trial design and implementation to improve diversity.

Novel Active Substances

• Decline in 2022 launches compared to 2021, but 115 nas launched the past five years as clinical and commercial potential grows.
• Much focus on treatments for rare cancers; oral therapy administration declining, favoring targeted biologic treatments.
• Treatment advances in patients with various cancers demonstrate significant clinical value, but access varies widely by geography.

Spending

• Global oncology spending rose to USD $196Bn in 2022, expected to reach $375Bn by 2027 due to new medicines and gains in access.
• China saw $6.8Bn increase in oncology spending over five years driven by new therapies and increased brand volume.
• Biosimilars now account for >50% uptake in many markets, generating substantial cost savings.

Outlook to 2027

• Oncology trials are projected to continue, with some trends potentially shifting due to geopolitical factors and evolving healthcare economics.
• Next-generation biotherapeutics face significant clinical and commercial uncertainty, but could substantially impact spending by 2027.
• Coming years promise continued evolution in oncology care but with unresolved issues of cost and diversity.

Methodologies, References, About the Institute & Authors